

# Adjunct Immunotherapies for the Management of Severe

Cell Reports Medicine

1, 100016

DOI: [10.1016/j.xcrm.2020.100016](https://doi.org/10.1016/j.xcrm.2020.100016)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PI3K $\gamma$ Inhibition as a Potential Therapeutic Target in COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 2094.	2.2	23
2	Harnessing Memory NK Cell to Protect Against COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 1309.	1.6	31
3	Immune dysfunction following COVID-19, especially in severe patients. <i>Scientific Reports</i> , 2020, 10, 15838.	1.6	56
4	Immune system changes during COVID-19 recovery play key role in determining disease severity. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842096649.	1.0	27
5	Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. <i>Clinical and Translational Immunology</i> , 2020, 9, e1192.	1.7	111
6	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. <i>Immunobiology</i> , 2020, 225, 152008.	0.8	65
7	Pharmaco-Immunomodulatory Therapy in COVID-19. <i>Drugs</i> , 2020, 80, 1267-1292.	4.9	208
8	The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy. <i>Chemical Biology and Drug Design</i> , 2020, 96, 1187-1208.	1.5	91
9	Obesity, COVID-19 and immunotherapy: the complex relationship!. <i>Immunotherapy</i> , 2020, 12, 1105-1109.	1.0	18
10	SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 582102.	2.2	31
11	The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. <i>Pharmacological Reports</i> , 2020, 72, 1529-1537.	1.5	8
12	Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection. <i>Cancers</i> , 2020, 12, 3383.	1.7	11
13	Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4899-4920.	2.7	73
14	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5224.	1.8	42
15	Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). <i>Clinical and Translational Immunology</i> , 2020, 9, e1198.	1.7	37
16	Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7937.	1.8	45
17	Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 1942.	2.2	18
18	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. <i>Clinical and Molecular Allergy</i> , 2020, 18, 17.	0.8	27

#	ARTICLE	IF	CITATIONS
19	Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. <i>Frontiers in Immunology</i> , 2020, 11, 570018.	2.2	43
20	A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102936.	0.5	14
21	Immunotherapy for SARS-CoV-2: potential opportunities. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1111-1116.	1.4	35
22	Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2020, 11, 586572.	2.2	69
23	Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?. <i>Frontiers in Immunology</i> , 2020, 11, 1239.	2.2	104
24	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. <i>Autophagy</i> , 2020, 16, 2260-2266.	4.3	54
25	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 1512.	2.2	126
26	On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. , 2020, 8, e001145.		48
27	Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?. <i>Frontiers in Immunology</i> , 2020, 11, 1248.	2.2	37
28	Potential of regulatory T-cell-based therapies in the management of severe COVID-19. <i>European Respiratory Journal</i> , 2020, 56, 2002182.	3.1	83
29	Targeting human TLRs to combat COVID-19: A solution?. <i>Journal of Medical Virology</i> , 2021, 93, 615-617.	2.5	91
30	Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 84-87.	1.4	19
31	Revisiting pharmacological potentials of <i>Nigella sativa</i> seed: A promising option for COVID-19 prevention and cure. <i>Phytotherapy Research</i> , 2021, 35, 1329-1344.	2.8	52
32	COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus. <i>International Immunopharmacology</i> , 2021, 90, 107220.	1.7	18
33	Human immunology and immunotherapy: main achievements and challenges. <i>Cellular and Molecular Immunology</i> , 2021, 18, 805-828.	4.8	96
34	Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. <i>Microorganisms</i> , 2021, 9, 121.	1.6	24
35	Review of pharmacologic and immunologic agents in the management of COVID-19. <i>Biosafety and Health</i> , 2021, 3, 148-155.	1.2	7
36	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167

#	ARTICLE	IF	CITATIONS
37	Low compositions of human toll-like receptor 7/8-stimulating RNA motifs in the MERS-CoV, SARS-CoV and SARS-CoV-2 genomes imply a substantial ability to evade human innate immunity. PeerJ, 2021, 9, e11008.	0.9	2
38	Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today, 2021, 36, 101051.	6.2	61
39	A Comparative Systematic Review of COVID-19 and Influenza. Viruses, 2021, 13, 452.	1.5	30
40	Natural Products from Medicinal Plants with Anti-Human Coronavirus Activities. Molecules, 2021, 26, 1754.	1.7	23
41	Epigenetic Lens to Visualize the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection in COVID-19 Pandemic. Frontiers in Genetics, 2021, 12, 581726.	1.1	28
42	Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opinion on Drug Safety, 2021, 20, 651-667.	1.0	4
43	Modeling Dendritic Cell Pulsed Immunotherapy for Mice with Melanoma—Protocols for Success and Recurrence. Applied Sciences (Switzerland), 2021, 11, 3199.	1.3	0
44	Type I Interferon Production of Plasmacytoid Dendritic Cells under Control. International Journal of Molecular Sciences, 2021, 22, 4190.	1.8	40
45	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. Journal of Biomaterials Science, Polymer Edition, 2021, 32, 1219-1249.	1.9	19
47	Exosomes contribution in COVID-19 patients' treatment. Journal of Translational Medicine, 2021, 19, 234.	1.8	25
48	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Frontiers in Immunology, 2021, 12, 658519.	2.2	63
49	Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application. Clinical Immunology, 2021, 227, 108727.	1.4	39
50	To Trap a Pathogen: Neutrophil Extracellular Traps and Their Role in Mucosal Epithelial and Skin Diseases. Cells, 2021, 10, 1469.	1.8	16
51	An overview of some potential immunotherapeutic options against COVID-19. International Immunopharmacology, 2021, 95, 107516.	1.7	7
52	COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype. Mini-Reviews in Organic Chemistry, 2021, 18, .	0.6	0
53	The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. International Immunopharmacology, 2021, 95, 107586.	1.7	26
54	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. Journal of Inflammation Research, 2021, Volume 14, 3419-3428.	1.6	25
55	The microbiota-related coinfections in COVID-19 patients: a real challenge. Beni-Suef University Journal of Basic and Applied Sciences, 2021, 10, 47.	0.8	9

#	ARTICLE	IF	CITATIONS
56	Surface Engineering of Graphene through Heterobifunctional Supramolecular-Covalent Scaffolds for Rapid COVID-19 Biomarker Detection. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 43696-43707.	4.0	13
57	Cellular Immunotherapy and the Lung. <i>Vaccines</i> , 2021, 9, 1018.	2.1	5
58	Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13101.	1.3	16
60	Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis. <i>Tuberculosis and Respiratory Diseases</i> , 2021, 84, 299-316.	0.7	13
61	Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. <i>Journal of Immunoassay and Immunochemistry</i> , 2020, 41, 960-975.	0.5	6
62	Autoimmunity as the comet tail of COVID-19 pandemic. <i>World Journal of Clinical Cases</i> , 2020, 8, 3621-3644.	0.3	50
64	Purification of polyclonal immunoglobulin G from human serum using peptide-based adsorbents. <i>AICHE Journal</i> , 2021, 67, e17482.	1.8	1
66	Use of Intravenous Immunoglobulin in the Treatment of Severe COVID-19 Disease – A Case Series. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 38-44.	0.1	0
67	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. <i>Gene Reports</i> , 2021, 25, 101417.	0.4	15
68	Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab <sup>2</sup> ) <sub>2</sub> fragment derived from equine polyclonal antibodies. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115796.	1.3	3
69	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Pathogens</i> , 2021, 10, 1537.	1.2	19
70	In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein. <i>Frontiers in Immunology</i> , 2021, 12, 782506.	2.2	24
71	Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?. <i>Biomedicines</i> , 2022, 10, 242.	1.4	14
72	Treating COVID-19: Evolving approaches to evidence in a pandemic. <i>Cell Reports Medicine</i> , 2022, 3, 100533.	3.3	7
73	Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1352, 87-109.	0.8	11
75	Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome. <i>Disability and Health Journal</i> , 2022, 15, 101278.	1.6	12
76	SARS-CoV-2 Induces Cytokine Responses in Human Basophils. <i>Frontiers in Immunology</i> , 2022, 13, 838448.	2.2	11
77	Cellular Therapy: The Hope for Covid-19. <i>Avicenna Journal of Medical Biotechnology</i> , 0, , .	0.2	2

#	ARTICLE	IF	CITATIONS
78	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. AAPS PharmSciTech, 2022, 23, 95.	1.5	3
79	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. Drug Design, Development and Therapy, 2022, Volume 16, 951-972.	2.0	4
80	MOLECULAR DOCKING STUDY ON PHYTOCONSTITUENTS OF TRADITIONAL AYURVEDIC DRUG TULSI (OCIMUM) Tj ETQq0 0 0 rgBT /Ove Pharmacy and Pharmaceutical Sciences, 0, , 44-50.	0.3	6
81	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Heliyon, 2022, 8, e09230.	1.4	16
82	Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159140.	1.2	10
83	Inhibitory Immune Checkpoint Molecules and Exhaustion of T cells in COVID-19. Physiological Research, 2021, 70, S227-S247.	0.4	13
84	Embelin Alleviates Severe Airway Inflammation in OVA-LPS-Induced Rat Model of Allergic Asthma. Journal of Asthma and Allergy, 2021, Volume 14, 1511-1525.	1.5	4
85	Cell movement and respiratory diseases. , 2022, , 237-244.		0
86	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. International Immunopharmacology, 2022, 109, 108786.	1.7	7
87	Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients. Frontiers in Immunology, 2022, 13, 878201.	2.2	5
88	Therapeutic approaches and vaccination in fighting COVID-19 infections: A review. Gene Reports, 2022, 27, 101619.	0.4	3
89	Reviving the mutual impact of SARS-COV-2 and obesity on patients: From morbidity to mortality. Biomedicine and Pharmacotherapy, 2022, 151, 113178.	2.5	8
90	Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality. Marmara Medical Journal, 0, , .	0.2	0
91	Immunotherapy as an emerging and promising tool against viral infections. , 2023, , 625-651.		0
92	Incursions by severe acute respiratory syndrome coronavirus-2 on the host anti-viral immunity during mild, moderate, and severe coronavirus disease 2019 disease. Exploration of Medicine, 0, , 794-811.	1.5	1
93	Thalidomide for the treatment of COVID-19 pneumonia: A randomized controlled clinical trial. Advanced Biomedical Research, 2023, 12, 14.	0.2	0
94	Role of natural killer and B cell interaction in inducing pathogen specific immune responses. International Reviews of Immunology, 2023, 42, 304-322.	1.5	1
95	Two Resveratrol Oligomers Inhibit Cathepsin L Activity to Suppress SARS-CoV-2 Entry. Journal of Agricultural and Food Chemistry, 2023, 71, 5535-5546.	2.4	4

#	ARTICLE	IF	CITATIONS
99	Plant Immunoenhancers: Promising Ethnopharmacological Candidates for Anti-SARS-CoV-2 Activity. , 2023, , 39-84.		0
102	Passive antibody therapy in emerging infectious diseases. <i>Frontiers of Medicine</i> , 2023, 17, 1117-1134.	1.5	2